Valby,
The final orderbook was significantly oversubscribed. The Notes are senior unsecured notes with a tenor of seven (7) years maturing
Nordea,
About the Programme:
The Programme was established in
The Base Prospectus dated
Lundbeck contacts
Investors: Media:
Vice President, Investor Relations Vice President,
Corporate
Communication
PALO@lundbeck.com JULZ@lundbeck.com
+45 30 83 24 26 +45 36 43 40 00
About
Millions of people worldwide live with brain diseases, and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement, and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.
Our approximately 5,800 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing, and sales. Our pipeline consists of several R&D programs, and our products are available in more than 100 countries. We have research centers in
For additional information, we encourage you to visit our corporate site www.lundbeck.com, and connect with us on Twitter at @Lundbeck and via LinkedIn.
DISCLAIMER:
This announcement does not constitute an offer or invitation to subscribe for the Notes and the offering does not constitute a public offering in any jurisdiction. Offer and distribution restrictions apply - see the base prospectus and the first supplement.
The manufacturer target market (MIFID II product governance) for the Notes is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as the Notes are not available to retail investors in the European Economic Area or in the
The Notes will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold in
This announcement is only directed at persons who (i) are outside the
This announcement serves as information to the market and is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation"). The Base Prospectus and supplement are available, and the Final Terms will (when published) be available, at https://investor.lundbeck.com/.
A rating is not a recommendation to buy, sell or hold securities and may be subject to revision, suspension or withdrawal at any time by the assigning rating organisation. Similar ratings for different types of issuers and on different types of securities do not necessarily mean the same thing. The significance of each rating should be analysed independently from any other rating.
Safe Harbor/Forward-Looking Statements
The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.
Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.
Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made considering past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/lundbeck-successfully-places-its-first-eur-500-million-eurobond-issue,c3212683
https://mb.cision.com/Main/18215/3212683/1316574.pdf
(c) 2020 Cision. All rights reserved., source